Fosun Pharma subsidiary gets green light for cancer drug trial

Shanghai Fosun Pharmaceutical (Group) Co.'s subsidiary, Xingsheng Xinhui, has received the go-ahead from Chinese regulators to commence clinical trials for its XS-03 tablets. The trials will evaluate XS-03 in combination with existing treatments (FOLFOX or FOLFIRI) and bevacizumab for metastatic colorectal cancer with RAS mutations. XS-03, a small molecule oral PLK1 inhibitor, has shown promising anti-tumor effects in preclinical models. As of January 2025, Fosun Pharma had invested approximately RMB 200 million in the R&D of this treatment regimen. While XS-03 monotherapy is in Phase I trials, the company cautions investors about the risks associated with drug development. Fosun Pharma will also proceed with Phase 1b/II clinical trials of the Treatment Regimen in China.